PMID- 37683061
OWN - NLM
STAT- MEDLINE
DCOM- 20230911
LR  - 20230911
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 22
IP  - 9
DP  - 2023 Sep 1
TI  - Review of Baricitinib in the Treatment of Alopecia Areata.
PG  - 935-940
LID - 10.36849/JDD.7357 [doi]
AB  - BACKGROUND: Alopecia areata (AA) is a debilitating autoimmune disease that 
      results in non-scarring hair loss. Baricitinib is the Food and Drug 
      Administration (FDA) approved treatment for AA.  Objective: Review the 
      mechanism of action, pharmacokinetics, pharmacodynamics, efficacy, and safety of 
      baricitinib in the treatment of AA.  Methods: A literature review was 
      conducted using the MEDLINE (PubMed) and EMBASE databases for articles published 
      between January 2010 to November 2022. Articles in English discussing 
      baricitinib's efficacy and safety in AA, pharmacodynamic, and pharmacokinetic 
      profiles were included. RESULTS: Two identical phase III trials (BRAVE-AA1 and 
      BRAVE-AA2) were evaluated. A greater percentage of subjects receiving baricitinib 
      4 mg or 2 mg dose achieved a Severity of Alopecia Tool score equal to or less 
      than 20 vs placebo. In BRAVE-AA1, for 4 mg, 2 mg, and placebo, respectively, 
      these values were 38.8%, 22.8%, and 6.2%; in BRAVE-AA2, these values were 35.9%, 
      19.4%, and 3.3% (P<0.001). DISCUSSION: Baricitinib is the first FDA-approved 
      treatment for AA. Other treatments for AA are used off-label with variable 
      efficacy. Baricitinib is associated with black-box warnings due to adverse 
      effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other 
      diseases. In the two large AA trials, AEs were considered mild or moderate; those 
      reported more often with baricitinib than placebo included acne, elevations of 
      low- and high-density lipoprotein cholesterol, and elevation of creatinine 
      kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative 
      for severe AA, although additional study is needed to assess its long-term 
      efficacy and safety.  Citation: Singh R, Driscoll MS. Review of baricitinib 
      in the treatment of alopecia areata. J Drugs Dermatol. 2023;22(9):935-939. 
      doi:10.36849/JDD.7357.
FAU - Singh, Rohan
AU  - Singh R
FAU - Driscoll, Marcia S
AU  - Driscoll MS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - ISP4442I3Y (baricitinib)
RN  - 0 (Azetidines)
RN  - 0 (Purines)
RN  - 0 (Janus Kinase Inhibitors)
RN  - Diffuse alopecia
SB  - IM
MH  - United States
MH  - Humans
MH  - *Alopecia Areata/diagnosis/drug therapy
MH  - *Azetidines/adverse effects
MH  - Purines/adverse effects
MH  - *Janus Kinase Inhibitors/adverse effects
EDAT- 2023/09/08 18:41
MHDA- 2023/09/11 06:42
CRDT- 2023/09/08 14:14
PHST- 2023/09/11 06:42 [medline]
PHST- 2023/09/08 18:41 [pubmed]
PHST- 2023/09/08 14:14 [entrez]
AID - S1545961623P0935X [pii]
AID - 10.36849/JDD.7357 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2023 Sep 1;22(9):935-940. doi: 10.36849/JDD.7357.